SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Metronidazole Tablets

Trade Name: Flagyl
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antibiotic agent, antiprotozoal agent.

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 2
Carcinogenicity: Category 2

EU Classification:

EU Indication of danger: Carcinogenic: Category 3
Toxic to Reproduction: Category 3

EU Risk Phrases:
R40 - Limited evidence of a carcinogenic effect
R63 - Possible risk of harm to the unborn child.

Label Elements

Signal Word: Warning
Hazard Statements: H351 - Suspected of causing cancer
H361d - Suspected of damaging the unborn child

Precautionary Statements: P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

Other Hazards No data available
Australian Hazard Classification (NOHSC): Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Metronidazole	443-48-1	207-136-1	Carc. Cat. 3, R40; Repr. Cat. 3, R63	Carc. 2, H351; Repr. 2, H361d	63.5
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	Not Listed	*
Titanium dioxide	13463-67-7	236-675-5	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
FD & C Blue No. 2, Aluminum lake	16521-38-3	240-589-3	Not Listed	Not Listed	*
Hydroxypropyl cellulose	9004-64-2	Not Listed	Not Listed	Not Listed	*
Hydroxypropyl methylcellulose	9004-65-3	Not Listed	Not Listed	Not Listed	*
Polyethylene glycol	25322-68-3	Not Listed	Not Listed	Not Listed	*
Stearic acid	57-11-4	200-313-4	Not Listed	Not Listed	*

Additional Information: * Proprietary
*** per tablet/capsule/lozenge/suppository
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: No data available

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store at room temperature in properly labeled containers. Keep away from heat, sparks and flames.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Metronidazole

Netherlands OEL - TWA	0.00012 mg/m^3

Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA)	10 mg/m^3
Australia TWA	10 mg/m^3
Belgium OEL - TWA	10 mg/m^3
Estonia OEL - TWA	10 mg/m^3
France OEL - TWA	10 mg/m^3
Ireland OEL - TWAs	10 mg/m^3 4 mg/m^3
Latvia OEL - TWA	2 mg/m^3
OSHA - Final PELS - TWAs:	15 mg/m^3
Portugal OEL - TWA	10 mg/m^3
Romania OEL - TWA	10 mg/m^3
Russia OEL - TWA	6 mg/m^3
Spain OEL - TWA	10 mg/m^3
Switzerland OEL -TWAs	3 mg/m^3
Vietnam OEL - TWAs	10 mg/m^3 5 mg/m^3

Polyethylene glycol

Austria OEL - MAKs	1000 mg/m^3
Germany - TRGS 900 - TWAs	1000 mg/m^3
Germany (DFG) - MAK	1000 mg/m^3 average molecular weight 200-600
Slovakia OEL - TWA	1000 mg/m^3
Slovenia OEL - TWA	1000 mg/m^3
Switzerland OEL -TWAs	1000 ppm

Titanium dioxide

ACGIH Threshold Limit Value (TWA)	10 mg/m^3
ACGIH OELs - Notice of Intended Changes	Listed
Australia TWA	10 mg/m^3
Austria OEL - MAKs	5 mg/m^3
Belgium OEL - TWA	10 mg/m^3
Bulgaria OEL - TWA	10.0 mg/m^3
Denmark OEL - TWA	6 mg/m^3
Estonia OEL - TWA	5 mg/m^3
France OEL - TWA	10 mg/m^3
Greece OEL - TWA	10 mg/m^3 5 mg/m^3
Ireland OEL - TWAs	10 mg/m^3 4 mg/m^3
Latvia OEL - TWA	10 mg/m^3
Lithuania OEL - TWA	5 mg/m^3

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

OSHA - Final PELS - TWAs:	15 mg/m^3
Poland OEL - TWA	10.0 mg/m^3
Portugal OEL - TWA	10 mg/m^3
Romania OEL - TWA	10 mg/m^3
Russia OEL - TWA	10 mg/m^3
Spain OEL - TWA	10 mg/m^3
Sweden OEL - TWAs	5 mg/m^3
Switzerland OEL -TWAs	3 mg/m^3
Vietnam OEL - TWAs	6 mg/m^3
	5 mg/m^3

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Metronidazole

Pfizer Occupational Exposure Band (OEB): OEB 2 (control exposure to the range of 100ug/m^3 to < 1000ug/m^3)

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablets	**Color:**	Blue
Odor:	No data available.	**Odor Threshold:**	No data available.
Molecular Formula:	Mixture	**Molecular Weight:**	Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
Metronidazole
No data available
Polyethylene glycol
No data available
Microcrystalline cellulose

9. PHYSICAL AND CHEMICAL PROPERTIES

No data available

Hydroxypropyl methylcellulose

No data available

Hydroxypropyl cellulose

No data available

Stearic acid

No data available

Titanium dioxide

No data available

FD & C Blue No. 2, Aluminum lake

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammablity:

- **Autoignition Temperature (Solid) (°C):** No data available
- **Flammability (Solids):** No data available
- **Flash Point (Liquid) (°C):** No data available
- **Upper Explosive Limits (Liquid) (% by Vol.):** No data available
- **Lower Explosive Limits (Liquid) (% by Vol.):** No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions

- **Oxidizing Properties:** No data available
- **Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.
- **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers
- **Hazardous Decomposition Products:** No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.
Long Term: Animal studies indicate that this material may cause adverse effects on the the developing fetus.
Known Clinical Effects: Clinical use of this drug has caused nausea, dizziness, and effects on blood forming organs.

Acute Toxicity: (Species, Route, End Point, Dose)

Metronidazole

Rat Oral LD 50 3 g/kg
Mouse Oral LD 50 3800mg/kg
Mouse Intraperitoneal LD 50 870mg/kg

11. TOXICOLOGICAL INFORMATION

Microcrystalline cellulose
Rat Oral LD50 > 5000 mg/kg
Rabbit Dermal LD50 > 2000 mg/kg

Hydroxypropyl methylcellulose
Rat Oral LD50 > 10,000 mg/kg

Stearic acid
Rat Oral LD50 > 4640 mg/kg
Rabbit Dermal LD50 > 5000mg/kg

Titanium dioxide
Rat Oral LD50 > 7500 mg/kg
Rat Subcutaneous LD50 50 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Metronidazole
Eye Irritation Rabbit No effect

Polyethylene glycol
Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Microcrystalline cellulose
Skin Irritation Rabbit Non-irritating
Eye Irritation Rabbit Non-irritating

Stearic acid
Skin Irritation Rabbit Moderate
Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Metronidazole
2 Year(s) Mouse Oral 600 mg/kg LOAEL
80 Week(s) Rat Oral 30 mg/kg LOAEL
34 Day(s) Rat Oral = 34 g/kg LOAEL Kidney, Ureter, Bladder
4 Month(s) Dog Oral 75 mg/kg LOAEL
1 Year(s) Non-human Primate Oral 150 mg/kg LOAEL

Stearic acid
30 Week(s) Rat Oral300 ppm LOAEL Adipose tissue

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Metronidazole
Reproductive & Fertility Rat Oral 400 mg/kg LOAEL Fertility
Reproductive & Fertility Rabbit Oral 200 mg/kg NOAEL Fertility, Developmental toxicity, Fetotoxicity

11. TOXICOLOGICAL INFORMATION

Embryo / Fetal Development Mouse Intraperitoneal 9 mg/kg LOAEL Fetotoxicity
Embryo / Fetal Development Rat Oral 200 mg/kg NOEL Not Teratogenic
Embryo / Fetal Development Mouse Intraperitoneal 40 mg/kg LOAEL Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Metronidazole
In Vitro Bacterial Mutagenicity (Ames) *Salmonella* Positive
In Vitro Sister Chromatid Exchange Hamster Negative
In Vivo Unscheduled DNA Synthesis Rabbit Negative
In Vivo Micronucleus Rat Negative
In Vitro Chromosome Aberration Human Lymphocytes Negative

Stearic acid
In Vitro Bacterial Mutagenicity (Ames) *Salmonella* Negative
Unscheduled DNA Synthesis *E. coli* Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Metronidazole
Not specified Rat Oral Tumors
Not specified Mouse Oral Tumors

Stearic acid
26 Week(s) Rat Subcutaneous 0.5 mg/kg/week NOAEL Not carcinogenic
52 Week(s) Mouse Subcutaneous 0.05 mg/kg/week LOAEL Tumors

Carcinogen Status: See below

Metronidazole
IARC: Group 2B (Possibly Carcinogenic to Humans)
NTP: Reasonably Anticipated To Be A Human Carcinogen

Titanium dioxide
IARC: Group 2B (Possibly Carcinogenic to Humans)
OSHA: Listed

12. ECOLOGICAL INFORMATION

Environmental Overview: The following information is available for the individual ingredients.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Metronidazole
Mysidopsis bahia (Mysid Shrimp) OECD LC-50 96 Hours >180 mg/L
Cyprinodon variegatus (Sheepshead Minnow) OECD LC-50 96 Hours >1060 mg/L
Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
Class D, Division 2, Subdivision A

FD & C Blue No. 2, Aluminum lake

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	240-589-3

Hydroxypropyl cellulose

CERCLA/SARA 313 Emission reporting	Not Listed

15. REGULATORY INFORMATION

California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Hydroxypropyl methylcellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

Metronidazole

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen initial date 1/1/88
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	207-136-1

Microcrystalline cellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex XVII - Restrictions on Certain Dangerous Substances:	Use restricted. See item 9[f]. powder
EU EINECS/ELINCS List	232-674-9

Polyethylene glycol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 3
EU EINECS/ELINCS List	Not Listed

Stearic acid

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-313-4

Titanium dioxide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen initial date 9/2/11 airborne, unbound particles of respirable size
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present

15. REGULATORY INFORMATION

EU EINECS/ELINCS List 236-675-5

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Carcinogenicity-Cat.2; H351 - Suspected of causing cancer
Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child

Carcinogenic: Category 3
Toxic to Reproduction: Category 3

R40 - Limited evidence of a carcinogenic effect
R63 - Possible risk of harm to the unborn child.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 3 - Composition / Information on Ingredients. Updated Section 2 - Hazard Identification. Updated Section 5 - Fire Fighting Measures. Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 12 - Ecological Information. Updated Section 13 - Disposal Considerations. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information.

Revision date: 02-May-2014

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet